Polymorphism rs3123554 in CNR2 reveals gender-specific effects on body weight and affects loss of body weight and cerebral insulin action

Obesity

Volumn 22, Issue 3, 2014, Pages 925-931

  Ketterer, Caroline ^a,b   Heni, Martin ^a   Stingl, Krunoslav ^a   Tschritter, Otto ^a   Linder, Katarzyna ^a,b   Wagner, Robert ^a   Machicao, Fausto ^a,b   Häring, Hans Ulrich ^a,b   Preissl, Hubert ^a,b,c   Staiger, Harald ^a,b   Fritsche, Andreas ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BRAIN FUNCTION; CEREBRAL INSULIN ACTION; CNR2 GENE; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; MAGNETOENCEPHALOGRAPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST HIP RATIO; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADMINISTRATION, INTRANASAL; ALLELES; BODY MASS INDEX; CEREBRUM; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DATABASES, GENETIC; DIABETES MELLITUS, TYPE 2; ELECTRIC IMPEDANCE; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB2; SEX CHARACTERISTICS; WEIGHT LOSS;

EID: 84895819571     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20573     Document Type: Article

References (40)

1. McCarthy MI,. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010; 363: 2339-2350.
2. Staiger H, Machicao F, Fritsche A, et al. Pathomechanisms of type 2 diabetes genes. Endocr Rev 2009; 30: 557-585.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
4. Haupt A, Thamer C, Heni M, et al. Gene variants of TCF7L2 influence weight loss and body composition during lifestyle intervention in a population at risk for type 2 diabetes. Diabetes 2010; 59: 747-750.
5. Kilpeläinen TO, Lakka TA, Laaksonen DE, et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc 2008; 40: 25-33.
6. Burch J, McKenna C, Palmer S, et al. Rimonabant for the treatment of overweight and obese people. Health Technol Assess 2009; 13 (Suppl 3): 13-22.
7. Onaivi ES, Ishiguro H, Gong J-P, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006; 1074: 514-536.
8. Morgan NH, Stanford IM, Woodhall GL,. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 2009; 57: 356-368.
9. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-332.
10. Brusco A, Tagliaferro P, Saez T, et al. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse 2008; 62: 944-949.
11. Schwartz MW, Woods SC, Porte D, Jr, et al. Central nervous system control of food intake. Nature 2000; 404: 661-671.
12. Tschritter O, Preissl H, Hennige AM, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci USA 2006; 103: 12103-12108.
13. Tschritter O, Preissl H, Hennige AM, et al. High cerebral insulin sensitivity is associated with loss of body fat during lifestyle intervention. Diabetologia 2012; 55: 175-182.
14. Matsuda M, DeFronzo RA,. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
15. Schäfer S, Kantartzis K, Machann J, et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 2007; 37: 535-543.
16. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
17. Machann J, Thamer C, Schnoedt B, et al. Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging 2005; 21: 455-462.
18. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326-1334.
19. Guthoff M, Stingl KT, Tschritter O, et al. The insulin-mediated modulation of visually evoked magnetic fields is reduced in obese subjects. PLoS One 2011; 6: e19482.
20. Heni M, Kullmann S, Ketterer C, et al. Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. Diabetologia 2012; 55: 1773-1782.
21. Stingl KT, Rogic̈ M, Stingl K, et al. The temporal sequence of magnetic brain activity for food categorization and memorization-an exploratory study. Neuroimage 2010; 52: 1584-1591.
22. Stingl KT, Kullmann S, Guthoff M, et al. Insulin modulation of magnetoencephalographic resting state dynamics in lean and obese subjects. Front Syst Neurosci 2010; 4: 157.
23. Haupt A, Thamer C, Machann J, et al. Impact of variation in the FTO gene on whole body fat distribution, ectopic fat, and weight loss. Obesity (Silver Spring) 2008; 16: 1969-1972.
24. Jablonski KA, McAteer JB, De Bakker PIW, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010; 59: 2672-2681.
25. Laukkanen O, Pihlajamäki J, Lindström J, et al. Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologia 2004; 47: 871-877.
26. Weyrich P, Stefan N, Häring H-U, et al. Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. J Mol Med 2007; 85: 107-117.
27. Hallschmid M, Schultes B,. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 2009; 52: 2264-2269.
28. Cota D, Marsicano G, Lutz B, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003; 27: 289-301.
29. Romero-Zerbo SY, Garcia-Gutierrez MS, Suárez J, et al. Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. J Neuroendocrinol 2012; 24: 1106-1119.
30. Onaivi ES, Carpio O, Ishiguro H, et al. Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann N Y Acad Sci 2008; 1139: 426-433.
31. Tesche CD, Karhu J,. Theta oscillations index human hippocampal activation during a working memory task. Proc Natl Acad Sci USA 2000; 97: 919-924.
32. Stoeckel LE, Weller RE, Cook EW III, et al. Widespread reward-system activation in obese women in response to pictures of high-calorie foods. Neuroimage 2008; 41: 636-647.
33. Dzoljic E, Van Leeuwen R, De Vries R, et al. Vigilance and EEG power in rats: effects of potent inhibitors of the neuronal nitric oxide synthase. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 56-61.
34. Kaplan R, Doeller CF, Barnes GR, et al. Movement-related theta rhythm in humans: coordinating self-directed hippocampal learning. PLoS Biol 2012; 10: e1001267.
35. Tschritter O, Haupt A, Preissl H, et al. An obesity risk SNP (rs17782313) near the MC4R gene is associated with cerebrocortical insulin resistance in humans. J Obes 2011; 2011: 283153.
36. Tschritter O, Preissl H, Yokoyama Y, et al. Variation in the FTO gene locus is associated with cerebrocortical insulin resistance in humans. Diabetologia 2007; 50: 2602-2603.
37. Cavuoto P, McAinch AJ, Hatzinikolas G, et al. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007; 364: 105-110.
38. Mallat A, Lotersztajn S,. Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 2006; 29: 58-65.
39. Roche R, Hoareau L, Bes-Houtmann S, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006; 126: 177-187.
40. Willems PJ, Seo HC, Coucke P, et al. Spectrum of mutations in fucosidosis. Eur J Hum Genet 1999; 7: 60-67.